Gilead Announces Sustained Virologic Response Rate of 78% From Phase 3 Study of Sofosbuvir for Genotype 2/3 Hepatitis C Infected Patients

Oprettet 29/11/2012 – 12:59

— POSITRON Demonstrates Efficacy of a 12-Week All-Oral Regimen of Sofosbuvir Plus Ribavirin for Chronic Hepatitis C Patients who are Unable or Unwilling to Take Interferon —

Skriv et svar

Din e-mailadresse vil ikke blive publiceret. Krævede felter er markeret med *